Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 9/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585629 | 0.93 | KMT2A (0.50) | KMT2ACSNK2A1MAPTMEN1CSNK2A2 | |
| SCHEMBL5585704 | 0.89 | CSNK2A1 (0.68) | KMT2ACSNK2A1MAPTMEN1LMNA | |
| SCHEMBL5585717 | 0.82 | ALOX5 (0.45) | KMT2ACSNK2A1MAPTMEN1CSNK2A2 | |
| SCHEMBL5585682 | 0.80 | CSNK2A1 (0.62) | KMT2ACSNK2A1MAPTMEN1LMNA | |
| SCHEMBL5585818 | 0.78 | PTGER1 (0.47) | CYP3A4CYP2C9 | |
| SCHEMBL5585751 | 0.77 | CSNK2A1 (0.59) | KMT2ACSNK2A1MAPTMEN1LMNA | |
| SCHEMBL28117026 | 0.77 | TUBB4A (0.67) | KMT2ACSNK2A1MAPTMEN1LMNA | |
| SCHEMBL5585445 | 0.77 | HPGDS (0.58) | KMT2ACSNK2A1MAPTMEN1SMN1; SMN2 | |
| SCHEMBL5585420 | 0.76 | CSNK2A1 (0.46) | KMT2ACSNK2A1MAPTMEN1LMNA | |
| SCHEMBL5585878 | 0.72 | PTGER1 (0.56) | MAPTCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | KMT2A 2589/4885CSNK2A1 124/4885MAPT 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.